Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback